ARTIVION, INC.

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues for cardiac and vascular surgical procedures, specifically for patients with aortic disease. The company has four main product families: aortic stent grafts, On-X mechanical heart valves and related surgical products, surgical sealants, and implantable cardiac and vascular human tissues. Aortic stent grafts include aortic arch stent grafts (such as E-vita Open NEO, E-vita Open Plus, Arcevo LSA Hybrid Stent Graft System, Ascyrus Medical Dissection Stent hybrid prosthesis, the NEXUS family of products including NEXUS ONE, NEXUS DUO, and NEXUS TRE, and E-vita Thoracic 3G products) and abdominal stent grafts (including E-xtra Design Engineering, E-nside, Artivex, E-tegra, E-ventus BX, Tuva BX, and E-liac products). Surgical sealants include BioGlue Surgical Adhesive products. Additionally, Artivion sells or distributes PhotoFix bovine surgical patches. The company began manufacturing and supplying PerClot hemostatic powder during the second quarter of 2023. Artivion operates through main subsidiaries including JOTEC GmbH, acquired on December 1, 2017, On-X Life Technologies, Inc., acquired on January 20, 2016, and Ascyrus Medical GmbH, acquired in September 2020, along with approximately twenty additional country entities for global sales and marketing. The company has two reportable segments: Medical Devices and Preservation Services.